再度入选高新技术企业公示名单 东北制药创新实力获国家权威认证

Core Viewpoint - Northeast Pharmaceutical Group has been recognized as a high-tech enterprise again, reflecting its strong capabilities in core technology research and development, as well as the transformation of scientific achievements [1][2]. Group 1: Recognition and Certification - The company has been included in the first batch of high-tech enterprises for 2025, as announced by the National High-tech Enterprise Recognition Management Work Leading Group Office [1]. - The high-tech enterprise recognition cycle is every three years, with strict requirements on the number of independent intellectual property rights, research projects, and the ability to transform scientific achievements [1]. Group 2: Research and Development Investment - The company has significantly increased its R&D investment, with a 95% year-on-year growth in R&D expenses in the first three quarters of this year [2]. - Major breakthroughs have been achieved in cutting-edge fields such as tumor immunotherapy, with multiple tumor-targeted cell therapy products under development [2]. Group 3: Strategic Importance of Recognition - The renewed recognition as a national high-tech enterprise will provide the company with tax benefits, policy support, and opportunities for high-end market collaborations, enhancing its core competitiveness and industry influence [2]. - The company currently owns five high-tech enterprises, creating a strong cluster of innovation capabilities within the group [3]. Group 4: Future Development Plans - The company plans to leverage this recognition to further increase R&D resource investment, accelerate the industrialization of scientific achievements, and optimize its product structure [3]. - The focus will be on enhancing core competitiveness and contributing to the high-quality development of the pharmaceutical industry [3].